Importantly, CDK4/6 inhibition also serves as an alternative dual HSF1-HSP90 inhibition strategy in p53-deficient cancer cells, providing a strategy for improving HSP90-based tumor therapies independent of the p53 status. This evidence concerns the gene HSP90AA1 and neoplasm.